| Literature DB >> 31625721 |
Haojie Liu1, Yan Hu2, Yajie Sun2, Chao Wan2, Zhanjie Zhang2, Xiaomeng Dai2, Zihan Lin1, Qianyuan He1, Zhe Yang1, Piao Huang1, Yuxuan Xiong1, Jinguo Cao1, Xu Chen1, Qi Chen1, Jonathan F Lovell3, Zushun Xu1, Honglin Jin2, Kunyu Yang2.
Abstract
Photodynamic therapy (PDT) is a clinical cancer treatment modality based on the induction of therapeutic reactive oxygen species (ROS), which can trigger immunogenic cell death (ICD). With the aim of simultaneously improving both PDT-mediated intracellular ROS production and ICD levels, we designed a serum albumin (SA)-coated boehmite ("B"; aluminum hydroxide oxide) organic-inorganic scaffold that could be loaded with chlorin e6 (Ce6), a photosensitizer, and a honey bee venom melittin (MLT) peptide, denoted Ce6/MLT@SAB. Ce6/MLT@SAB was anchored by a boehmite nanorod structure and exhibited particle size of approximately 180 nm. Ce6/MLT@SAB could significantly reduce hemolysis relative to that of free MLT, while providing MLT-enhanced PDT antitumor effects in vitro. Compared with Ce6@SAB, Ce6/MLT@SAB improved Ce6 penetration of cancer cells both in vitro and in vivo, thereby providing enhanced intracellular ROS generation with 660 nm light treatment. Following phototreatment, Ce6/MLT@SAB-treated cells displayed significantly improved levels of ICD and abilities to activate dendritic cells. In the absence of laser irradiation, multidose injection of Ce6/MLT@SAB could delay the growth of subcutaneous murine tumors by more than 60%, compared to controls. When combined with laser irradiation, a single injection and phototreatment with Ce6/MLT@SAB eradicated one-third of subcutaneous tumors in treated mice. The addition of an immune checkpoint blockade to Ce6/MLT@SAB phototreatment further augmented antitumor effects, generating increased numbers of CD4+ and CD8+ T cells in tumors with concomitant reduction of myeloid-derived suppressor cells.Entities:
Keywords: anti-PD-1; cancer immunotherapy; immune checkpoints; immunogenic cell death; melittin; photodynamic therapy
Year: 2019 PMID: 31625721 DOI: 10.1021/acsnano.9b04181
Source DB: PubMed Journal: ACS Nano ISSN: 1936-0851 Impact factor: 15.881